Sanofi Dupixent Type 2 Inflammation 2020

Sanofi investor relations presentation on Dupixent®, a biologic developed with Regeneron for Type 2 inflammation indications. The event covers commercial success in atopic dermatitis and asthma, explores the mechanisms of Type 2 inflammation, and discusses pipeline expansion opportunities in related diseases.